Erika Sutanto‐Ward

2.0k total citations · 1 hit paper
22 papers, 1.6k citations indexed

About

Erika Sutanto‐Ward is a scholar working on Molecular Biology, Biological Psychiatry and Oncology. According to data from OpenAlex, Erika Sutanto‐Ward has authored 22 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Biological Psychiatry and 8 papers in Oncology. Recurrent topics in Erika Sutanto‐Ward's work include Tryptophan and brain disorders (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers) and Immune cells in cancer (5 papers). Erika Sutanto‐Ward is often cited by papers focused on Tryptophan and brain disorders (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers) and Immune cells in cancer (5 papers). Erika Sutanto‐Ward collaborates with scholars based in United States, France and Ireland. Erika Sutanto‐Ward's co-authors include Alexander J. Muller, James B. DuHadaway, George C. Prendergast, Preston S. Donover, Alejandro Peralta Soler, Janette Boulden, Laura Mandik‐Nayak, Courtney Smith, Mee Young Chang and Lisa D. Laury‐Kleintop and has published in prestigious journals such as Nature Medicine, Cancer Research and Oncogene.

In The Last Decade

Erika Sutanto‐Ward

21 papers receiving 1.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

2005 873 citations Alexander J. Muller, James B. DuHadaway et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erika Sutanto‐Ward United States	14	876	597	544	414	282	22	1.6k
Lisa D. Laury‐Kleintop United States	19	739 0.8×	581 1.0×	610 1.1×	392 0.9×	273 1.0×	36	1.8k
Preston S. Donover United States	11	559 0.6×	354 0.6×	498 0.9×	284 0.7×	184 0.7×	18	1.2k
Kevin Bowman United States	8	430 0.5×	205 0.3×	262 0.5×	200 0.5×	198 0.7×	17	825
Jen‐Shin Song Taiwan	22	181 0.2×	150 0.3×	625 1.1×	273 0.7×	89 0.3×	58	1.4k
Rogier C. Buijsman Netherlands	20	128 0.1×	103 0.2×	566 1.0×	230 0.6×	54 0.2×	49	1.3k
Pradeep Bista United States	11	73 0.1×	321 0.5×	793 1.5×	185 0.4×	34 0.1×	20	1.5k
Sowmya Chollate United States	6	72 0.1×	269 0.5×	650 1.2×	149 0.4×	29 0.1×	6	1.3k
Sazzad Hassan United States	20	16 0.0×	110 0.2×	547 1.0×	363 0.9×	206 0.7×	35	1.3k
Rebecca Conrad Germany	6	63 0.1×	240 0.4×	500 0.9×	106 0.3×	22 0.1×	6	1.1k
Chantal Bazenet United Kingdom	21	45 0.1×	143 0.2×	1.1k 2.1×	162 0.4×	202 0.7×	29	1.7k

Countries citing papers authored by Erika Sutanto‐Ward

Since Specialization

Citations

This map shows the geographic impact of Erika Sutanto‐Ward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erika Sutanto‐Ward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erika Sutanto‐Ward more than expected).

Fields of papers citing papers by Erika Sutanto‐Ward

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erika Sutanto‐Ward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erika Sutanto‐Ward. The network helps show where Erika Sutanto‐Ward may publish in the future.

Co-authorship network of co-authors of Erika Sutanto‐Ward

This figure shows the co-authorship network connecting the top 25 collaborators of Erika Sutanto‐Ward. A scholar is included among the top collaborators of Erika Sutanto‐Ward based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erika Sutanto‐Ward. Erika Sutanto‐Ward is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dey, Souvik, James B. DuHadaway, Erika Sutanto‐Ward, et al.. (2025). Neovascular pruning by IDO1 inhibitors can potentiate immunogenic cytotoxicity of ischemia-targeted agents to synergistically enhance anti-PD-1 responsiveness. Journal for ImmunoTherapy of Cancer. 13(5). e011398–e011398. 1 indexed citations

Chapellier, Marion, Evelina Martinenaite, Shamaila Munir Ahmad, et al.. (2024). Abstract 4094: Immune modulatory cancer vaccines against IDO1 and PD-L1 trigger distinct pathways and cooperatively reduce tumor growth in preclinical models. Cancer Research. 84(6_Supplement). 4094–4094. 1 indexed citations

Dey, Souvik, Arpita Mondal, James B. DuHadaway, et al.. (2021). IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization. Cancer Immunology Research. 9(5). 514–528. 24 indexed citations

Dey, Souvik, Erika Sutanto‐Ward, Katharina Kopp, et al.. (2020). Peptide vaccination directed against IDO1-expressing immune cells elicits CD8⁺ and CD4⁺ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. Journal for ImmunoTherapy of Cancer. 8(2). e000605–e000605. 36 indexed citations

Nevler, Avinoam, Alexander J. Muller, Erika Sutanto‐Ward, et al.. (2018). Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS -Driven Sporadic Pancreatic Cancers. Clinical Cancer Research. 25(2). 724–734. 41 indexed citations

Mondal, Arpita, Courtney Smith, James B. DuHadaway, et al.. (2016). IDO1 is an Integral Mediator of Inflammatory Neovascularization. EBioMedicine. 14. 74–82. 75 indexed citations

Smith, Courtney, Mee Young Chang, Katherine H. Parker, et al.. (2012). IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development. Cancer Discovery. 2(8). 722–735. 260 indexed citations

Muller, Alexander J., James B. DuHadaway, Mee Young Chang, et al.. (2010). Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunology Immunotherapy. 59(11). 1655–1663. 43 indexed citations

Ramalingam, Arivudainambi, James B. DuHadaway, Erika Sutanto‐Ward, et al.. (2008). Bin3 Deletion Causes Cataracts and Increased Susceptibility to Lymphoma during Aging. Cancer Research. 68(6). 1683–1690. 23 indexed citations

10.

Chang, Mee Young, Janette Boulden, Erika Sutanto‐Ward, et al.. (2007). Bin1 Ablation in Mammary Gland Delays Tissue Remodeling and Drives Cancer Progression. Cancer Research. 67(1). 100–107. 36 indexed citations

11.

Banerjee, Tinku, James B. DuHadaway, Paul Gaspari, et al.. (2007). A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene. 27(20). 2851–2857. 150 indexed citations

12.

Muller, Alexander J., James B. DuHadaway, Erika Sutanto‐Ward, Preston S. Donover, & George C. Prendergast. (2005). Transcriptional control of IDO by the cancer suppression gene Bin1, a key mechanism for restraining tumor immune escape. Cancer Research. 65. 1255–1255. 1 indexed citations

13.

Muller, Alexander J., James B. DuHadaway, Preston S. Donover, Erika Sutanto‐Ward, & George C. Prendergast. (2005). Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine. 11(3). 312–319. 873 indexed citations breakdown →

14.

Muller, Alexander J., James B. DuHadaway, Preston S. Donover, Erika Sutanto‐Ward, & George C. Prendergast. (2004). Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biology & Therapy. 3(12). 1236–1242. 17 indexed citations

15.

Watson, James C., et al.. (1999). Importance of timing and length of administration of angiogenesis inhibitor TNP-470 in the treatment of K12/TRb colorectal hepatic metastases in BD-IX rats. Surgery. 126(2). 358–363. 1 indexed citations

16.

Sutanto‐Ward, Erika, et al.. (1996). Regional chemotherapy for colorectal hepatic metastases: Evidence for improved survival with new drug combinations. Annals of Surgical Oncology. 3(1). 36–43. 4 indexed citations

17.

Arisawa, Yoshito, Erika Sutanto‐Ward, Lucio Fortunato, & Elin R. Sigurdson. (1995). Hepatic artery dexamethasone infusion inhibits colorectal hepatic metastases: A regional antiangiogenic therapy. Annals of Surgical Oncology. 2(2). 114–120. 15 indexed citations

18.

Arisawa, Yoshito, Erika Sutanto‐Ward, Rory R. Dalton, & Elin R. Sigurdson. (1994). Short‐term intrahepatic FUdR infusion combined with bolus mitomycin C: Reduced risk for developing drug resistance. Journal of Surgical Oncology. 56(2). 75–80. 4 indexed citations

19.

Sutanto‐Ward, Erika, et al.. (1992). Adjuvant chemotherapy for colorectal hepatic metastases: role of route of administration and timing. Surgical Oncology. 1(1). 87–95. 17 indexed citations

20.

Mahmood, Umar, et al.. (1992). Quantitation of total metastatic tumor volume in the rat liver: Correlation of MR and histologic measurements. Journal of Magnetic Resonance Imaging. 2(3). 335–340. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact